{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:47:54Z","timestamp":1782182874919,"version":"3.54.5"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,22]]},"DOI":"10.7759\/cureus.111322","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:28:30Z","timestamp":1782181710000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence"],"prefix":"10.7759","author":[{"given":"Brij","family":"Teli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Sathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituprana","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh","family":"Kunwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin R","family":"Kahale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sinkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Palimkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Magdum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Nivargi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jignesh","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjeet","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Kashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Thopte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Lakade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagjeet","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Dhoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhushan","family":"Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Munot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Mane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omkar","family":"Thopte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikrant","family":"Khese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DB","family":"Gaware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Bharmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Khadtare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular\u00a0diseases and risk: a compass for future health","volume":"80","author":"Vaduganathan M","year":"2022","unstructured":"Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular\u00a0diseases and risk: a compass for future health. J Am Coll Cardiol. 2022, 80:2361-71. 10.1016\/j.jacc.2022.11.005","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.101326","article-title":"Global trends in cardiovascular mortality attributable to high body mass index: 1990-2021 analysis with future projections","volume":"24","author":"Fallahtafti P","year":"2025","unstructured":"Fallahtafti P, Soleimani H, Khanmohammadi S, et al.. Global trends in cardiovascular mortality attributable to high body mass index: 1990-2021 analysis with future projections. Am J Prev Cardiol. 2025, 24:101326. 10.1016\/j.ajpc.2025.101326","journal-title":"Am J Prev Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028409","article-title":"Racial disparities in obesity-related cardiovascular mortality in the United States: temporal trends from 1999 to 2020","volume":"12","author":"Raisi-Estabragh Z","year":"2023","unstructured":"Raisi-Estabragh Z, Kobo O, Mieres JH, Bullock-Palmer RP, Van Spall HG, Breathett K, Mamas MA. Racial disparities in obesity-related cardiovascular mortality in the United States: temporal trends from 1999 to 2020. J Am Heart Assoc. 2023, 12:e028409. 10.1161\/JAHA.122.028409","journal-title":"J Am Heart Assoc"},{"key":"ref4","unstructured":"Racial and ethnic disparities in heart disease. (2019). Accessed. May 18, 2026: https:\/\/www.cdc.gov\/nchs\/hus\/spotlight\/HeartDiseaseSpotlight_2019_0404.pdf."},{"key":"ref5","unstructured":"World Obesity Atlas 2025. (2025). Accessed. May 18, 2026: https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2025."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-025-00637-9","article-title":"Metabolically healthy obesity and metabolic dysfunction-associated steatotic liver disease (MASLD): navigating the controversies in disease development and progression","volume":"14","author":"Koliaki C","year":"2025","unstructured":"Koliaki C, Dalamaga M, Kakounis K, Liatis S. Metabolically healthy obesity and metabolic dysfunction-associated steatotic liver disease (MASLD): navigating the controversies in disease development and progression. Curr Obes Rep. 2025, 14:46. 10.1007\/s13679-025-00637-9","journal-title":"Curr Obes Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall JE","year":"2015","unstructured":"Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015, 116:991-1006. 10.1161\/CIRCRESAHA.116.305697","journal-title":"Circ Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X202010022","article-title":"Obesity as a predictive factor for chronic kidney disease in adults: systematic review and meta-analysis","volume":"54","author":"Pinto KR","year":"2021","unstructured":"Pinto KR, Feckinghaus CM, Hirakata VN. Obesity as a predictive factor for chronic kidney disease in adults: systematic review and meta-analysis. Braz J Med Biol Res. 2021, 54:e10022. 10.1590\/1414-431X202010022","journal-title":"Braz J Med Biol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.639922","article-title":"Obesity: a stubbornly obvious target for stroke prevention","volume":"44","author":"Kernan WN","year":"2013","unstructured":"Kernan WN, Inzucchi SE, Sawan C, Macko RF, Furie KL. Obesity: a stubbornly obvious target for stroke prevention. Stroke. 2013, 44:278-86. 10.1161\/STROKEAHA.111.639922","journal-title":"Stroke"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2013.12.005","article-title":"Mechanisms of heart failure in obesity","volume":"8","author":"Ebong IA","year":"2014","unstructured":"Ebong IA, Goff DC Jr, Rodriguez CJ, Chen H, Bertoni AG. Mechanisms of heart failure in obesity. Obes Res Clin Pract. 2014, 8:e540-8. 10.1016\/j.orcp.2013.12.005","journal-title":"Obes Res Clin Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2017.04.013","article-title":"Obesity in coronary heart disease: an unaddressed behavioral risk factor","volume":"104","author":"Ades PA","year":"2017","unstructured":"Ades PA, Savage PD. Obesity in coronary heart disease: an unaddressed behavioral risk factor. Prev Med. 2017, 104:117-9. 10.1016\/j.ypmed.2017.04.013","journal-title":"Prev Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and cardiovascular disease: an ESC clinical consensus statement","volume":"45","author":"Koskinas KC","year":"2024","unstructured":"Koskinas KC, Van Craenenbroeck EM, Antoniades C, et al.. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J. 2024, 45:4063-98. 10.1093\/eurheartj\/ehae508","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley TM","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, et al.. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021, 143:e984-1010. 10.1161\/CIR.0000000000000973","journal-title":"Circulation"},{"key":"ref14","article-title":"Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity","volume":"11","author":"Henning RJ","year":"2021","unstructured":"Henning RJ. Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. Am J Cardiovasc Dis. 2021, 11:504-29.","journal-title":"Am J Cardiovasc Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","volume":"86","author":"Packer M","year":"2025","unstructured":"Packer M. The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment. J Am Coll Cardiol. 2025, 86:1269-373. 10.1016\/j.jacc.2025.06.055","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27031186","article-title":"Semaglutide-mediated remodeling of adipose tissue in type 2 diabetes: molecular mechanisms beyond glycemic control","volume":"27","author":"\u00c1bel T","year":"2026","unstructured":"\u00c1bel T, Csobod Csajb\u00f3kn\u00e9 \u00c9. Semaglutide-mediated remodeling of adipose tissue in type 2 diabetes: molecular mechanisms beyond glycemic control. Int J Mol Sci. 2026, 27:1186. 10.3390\/ijms27031186","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng H","year":"2024","unstructured":"Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024, 23:346. 10.1186\/s12933-024-02434-5","journal-title":"Cardiovasc Diabetol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808721","article-title":"Cardiovascular safety of lorcaserin in overweight or obese patients","volume":"379","author":"Bohula EA","year":"2018","unstructured":"Bohula EA, Wiviott SD, McGuire DK, et al.. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018, 379:1107-17. 10.1056\/NEJMoa1808721","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James WP","year":"2010","unstructured":"James WP, Caterson ID, Coutinho W, et al.. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010, 363:905-17. 10.1056\/NEJMoa1003114","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60935-X","article-title":"Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial","volume":"376","author":"Topol EJ","year":"2010","unstructured":"Topol EJ, Bousser MG, Fox KA, et al.. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010, 376:517-23. 10.1016\/S0140-6736(10)60935-X","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132835","article-title":"Anti-inflammatory drugs in patients with ischemic heart disease","volume":"10","author":"Pello L\u00e1zaro AM","year":"2021","unstructured":"Pello L\u00e1zaro AM, Blanco-Colio LM, Franco Pel\u00e1ez JA, Tu\u00f1\u00f3n J. Anti-inflammatory drugs in patients with ischemic heart disease. J Clin Med. 2021, 10:2835. 10.3390\/jcm10132835","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1558","article-title":"Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial","volume":"315","author":"Nissen SE","year":"2016","unstructured":"Nissen SE, Wolski KE, Prcela L, et al.. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016, 315:990-1004. 10.1001\/jama.2016.1558","journal-title":"JAMA"},{"key":"ref24","unstructured":"Google Patents. US20230332200A1-a process for the preparation of semaglutide and semapeptide. Accessed. May 18, 2026: https:\/\/patents.google.com\/patent\/US20230332200A1\/en."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.108999","article-title":"Semaglutide and follow-on peptide therapeutics: balancing innovation, regulation, and clinical outcomes","volume":"18","author":"Teli B","year":"2026","unstructured":"Teli B, Somani S, Arya V, et al.. Semaglutide and follow-on peptide therapeutics: balancing innovation, regulation, and clinical outcomes. Cureus. 2026, 18:e108999. 10.7759\/CUREUS.108999","journal-title":"Cureus"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70686","article-title":"Lower risk of cardiovascular events in patients with clinical atherosclerotic cardiovascular disease who initiated semaglutide 2.4\u2009mg in the real-world: results from the SCORE-clinical ASCVD study","volume":"28","author":"Nanna MG","year":"2026","unstructured":"Nanna MG, Mena-Hurtado C, Divino V, et al.. Lower risk of cardiovascular events in patients with clinical atherosclerotic cardiovascular disease who initiated semaglutide 2.4\u2009mg in the real-world: results from the SCORE-clinical ASCVD study. Diabetes Obes Metab. 2026, 28:4975-90. 10.1111\/dom.70686","journal-title":"Diabetes Obes Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/20565623.2025.2483607","article-title":"The multifaceted effects of semaglutide: exploring its broad therapeutic\u00a0applications","volume":"11","author":"Alkhatib M","year":"2025","unstructured":"Alkhatib M, Almasri N, Alshwayyat S, et al.. The multifaceted effects of semaglutide: exploring its broad therapeutic\u00a0applications. Future Sci OA. 2025, 11:2483607. 10.1080\/20565623.2025.2483607","journal-title":"Future Sci OA"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref30","unstructured":"List of new drugs (r-DNA origin) approved for import and marketing in India during Jan, 2020-Jan, 2025. https.\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadBiologicalrDNA\/CT-18A%20Approvals%20Jan."},{"key":"ref31","article-title":"Atherosclerotic cardiovascular diseases","author":"National Research Council (US) Committee on Diet and Health","year":"1989","unstructured":"National Research Council (US) Committee on Diet and Health. Atherosclerotic cardiovascular diseases. Diet and Health: Implications for Reducing Chronic Disease Risk. National Academies Press (US), Washington (DC); 1989."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-35819-7_21","article-title":"Heart failure with preserved ejection fraction (HFpEF)","author":"Tennyson CD","year":"2023","unstructured":"Tennyson CD. Heart failure with preserved ejection fraction (HFpEF). Cardiovascular Manual for the Advanced Practice Provider. Musialowski R, Allshouse K (ed): Springer, Cham; 2023. 221-4. 10.1007\/978-3-031-35819-7_21"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcag029","article-title":"Heart failure with reduced ejection fraction: a systematic review of clinical practice guidelines and recommendations","author":"Datta S","year":"2026","unstructured":"Datta S, Majumder S, Gulsin GS, et al.. Heart failure with reduced ejection fraction: a systematic review of clinical practice guidelines and recommendations. Eur Heart J Qual Care Clin Outcomes. 2026, qcag029. 10.1093\/ehjqcco\/qcag029","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.08.007","article-title":"Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic\/obese HFpEF","volume":"6","author":"Kitzman DW","year":"2018","unstructured":"Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic\/obese HFpEF. JACC Heart Fail. 2018, 6:1008-10. 10.1016\/j.jchf.2018.08.007","journal-title":"JACC Heart Fail"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug BA","year":"2023","unstructured":"Borlaug BA, Jensen MD, Kitzman DW, Lam CS, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023, 118:3434-50. 10.1093\/cvr\/cvac120","journal-title":"Cardiovasc Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100731","article-title":"Epicardial adipose tissue in obese heart\u00a0failure with preserved ejection fraction: the evidence grows","volume":"2","author":"Obokata M","year":"2023","unstructured":"Obokata M, Kagami K. Epicardial adipose tissue in obese heart\u00a0failure with preserved ejection fraction: the evidence grows. JACC Adv. 2023, 2:100731. 10.1016\/j.jacadv.2023.100731","journal-title":"JACC Adv"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100730","article-title":"Obesity-related differences in pathomechanism and outcomes in patients with HFpEF: a CMR study","volume":"2","author":"Nakamori S","year":"2023","unstructured":"Nakamori S, Kucukseymen S, Rodriguez J, et al.. Obesity-related differences in pathomechanism and outcomes in patients with HFpEF: a CMR study. JACC Adv. 2023, 2:100730. 10.1016\/j.jacadv.2023.100730","journal-title":"JACC Adv"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey WT","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al.. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022, 28:2083-91. 10.1038\/s41591-022-02026-4","journal-title":"Nat Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial","volume":"5","author":"Aroda VR","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al.. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017, 5:355-66. 10.1016\/S2213-8587(17)30085-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield J","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, et al.. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024, 404:773-86. 10.1016\/S0140-6736(24)01498-3","journal-title":"Lancet"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic V","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al.. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024, 391:109-21. 10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-84. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al.. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024, 390:1394-407. 10.1056\/NEJMoa2313917","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal AJ","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025, 392:2089-99. 10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca MP","year":"2025","unstructured":"Bonaca MP, Catarig AM, Houlind K, et al.. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025, 405:1580-93. 10.1016\/S0140-6736(25)00509-4","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx N","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, et al.. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023, 44:4043-140. 10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints C","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, et al.. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024, 45:3415-537. 10.1093\/eurheartj\/ehae177","journal-title":"Eur Heart J"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-86. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06196-3","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary","volume":"67","author":"European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity","year":"2024","unstructured":"European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary. Diabetologia. 2024, 67:2375-92. 10.1007\/s00125-024-06196-3","journal-title":"Diabetologia"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.07.017","article-title":"American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease-2025 update","volume":"31","author":"Nadolsky K","year":"2025","unstructured":"Nadolsky K, Garvey WT, Agarwal M, et al.. American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease-2025 update. Endocr Pract. 2025, 31:1351-94. 10.1016\/j.eprac.2025.07.017","journal-title":"Endocr Pract"},{"key":"ref52","unstructured":"Obesity Canada. Canadian adult obesity clinical practice guideline. Accessed. May 18, 2026: https:\/\/obesitycanada.ca\/healthcare-professionals\/adult-clinical-practice-guideline\/."},{"key":"ref53","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Diabetes Work Group: KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022, 102:S1-127.","journal-title":"Kidney Int"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.4081\/cardio.2025.70","article-title":"iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025","volume":"36","author":"Chopra V","year":"2025","unstructured":"Chopra V, Zieroth S. iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025. Cardiovasc J Afr. 2025, 36:35-62. 10.4081\/cardio.2025.70","journal-title":"Cardiovasc J Afr"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Gornik HL","year":"2024","unstructured":"Gornik HL, Aronow HD, Goodney PP, et al.. 2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024, 83:2497-604. 10.1016\/j.jacc.2024.02.013","journal-title":"J Am Coll Cardiol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23621","article-title":"Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics","volume":"31","author":"Lingvay I","year":"2023","unstructured":"Lingvay I, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring). 2023, 31:111-22. 10.1002\/oby.23621","journal-title":"Obesity (Silver Spring)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design","volume":"229","author":"Ryan DH","year":"2020","unstructured":"Ryan DH, Lingvay I, Colhoun HM, et al.. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020, 229:61-9. 10.1016\/j.ahj.2020.07.008","journal-title":"Am Heart J"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03176-w","article-title":"The composite number needed to treat for semaglutide in populations with overweight or obesity and established cardiovascular disease without diabetes","volume":"42","author":"L\u00fcbker C","year":"2025","unstructured":"L\u00fcbker C, Bhavsar J, Duque do Vale R, et al.. The composite number needed to treat for semaglutide in populations with overweight or obesity and established cardiovascular disease without diabetes. Adv Ther. 2025, 42:2513-25. 10.1007\/s12325-025-03176-w","journal-title":"Adv Ther"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2025.10.206","article-title":"Early clinical benefit of semaglutide in adults with overweight or obesity and cardiovascular disease: a secondary analysis of the SELECT trial","volume":"119","author":"Shiele F","year":"2026","unstructured":"Shiele F, Plutzky J, Ostrominski JW, et al.. Early clinical benefit of semaglutide in adults with overweight or obesity and cardiovascular disease: a secondary analysis of the SELECT trial. Arch Cardiovasc Dis. 2026, 119:S116-7. 10.1016\/j.acvd.2025.10.206","journal-title":"Arch Cardiovasc Dis"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.2792","article-title":"Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial","volume":"45","author":"Colhoun H","year":"2024","unstructured":"Colhoun H, Lincoff AM, Linder M, et al.. Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial. Eur Heart J. 2024, 45:10.1093\/eurheartj\/ehae666.2792","journal-title":"Eur Heart J"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70080","article-title":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4\u2009mg in the real-world: results from the SCORE study (semaglutide effects on cardiovascular outcomes in people with overweight or obesity in the real world)","volume":"27","author":"Smolderen KG","year":"2025","unstructured":"Smolderen KG, Mena-Hurtado C, Zhao Z, et al.. Lower risk of cardiovascular events in patients initiated on semaglutide 2.4\u2009mg in the real-world: results from the SCORE study (semaglutide effects on cardiovascular outcomes in people with overweight or obesity in the real world). Diabetes Obes Metab. 2025, 27:6691-704. 10.1111\/dom.70080","journal-title":"Diabetes Obes Metab"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70436","article-title":"Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)","volume":"28","author":"Wilson L","year":"2026","unstructured":"Wilson L, Zhao Z, Divino V, Bassan M, Hartaigh B\u00d3, Stensen S, Ozer K. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER). Diabetes Obes Metab. 2026, 28:2403-15. 10.1111\/dom.70436","journal-title":"Diabetes Obes Metab"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.11.008","article-title":"Semaglutide improves cardiovascular outcomes in patients with history of\u00a0coronary artery bypass graft and\u00a0obesity","volume":"85","author":"Verma S","year":"2025","unstructured":"Verma S, Emerson S, Plutzky J, et al.. Semaglutide improves cardiovascular outcomes in patients with history of\u00a0coronary artery bypass graft and\u00a0obesity. J Am Coll Cardiol. 2025, 85:541-5. 10.1016\/j.jacc.2024.11.008","journal-title":"J Am Coll Cardiol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.807289","article-title":"Body mass index and vigorous physical activity and the risk of heart failure among men","volume":"119","author":"Kenchaiah S","year":"2009","unstructured":"Kenchaiah S, Sesso HD, Gaziano JM. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation. 2009, 119:44-52. 10.1161\/CIRCULATIONAHA.108.807289","journal-title":"Circulation"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-009-0006-9","article-title":"Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia","volume":"9","author":"Gutierrez DA","year":"2009","unstructured":"Gutierrez DA, Puglisi MJ, Hasty AH. Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Curr Diab Rep. 2009, 9:26-32. 10.1007\/s11892-009-0006-9","journal-title":"Curr Diab Rep"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler J","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC, et al.. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024, 403:1635-48. 10.1016\/S0140-6736(24)00469-0","journal-title":"Lancet"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.05.008","article-title":"2025 ACC scientific statement on the management of obesity in adults with heart failure: a report of the American College of Cardiology","volume":"86","author":"Kittleson MM","year":"2025","unstructured":"Kittleson MM, Benjamin EJ, Blumer V, Harrington J, Januzzi JL, McMurray JJ, Vest AR. 2025 ACC scientific statement on the management of obesity in adults with heart failure: a report of the American College of Cardiology. J Am Coll Cardiol. 2025, 86:1953-75. 10.1016\/j.jacc.2025.05.008","journal-title":"J Am Coll Cardiol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.2337\/DOCI25-0008","article-title":"Pharmacologic treatment of obesity in adults: standards of care in overweight and obesity","volume":"1","author":"American Diabetes Association Professional Practice Committee for Obesity","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: standards of care in overweight and obesity. Diabetes, Obesity, and CardioMetabolic CARE. 2026, 1:5-36. 10.2337\/DOCI25-0008","journal-title":"Diabetes, Obesity, and CardioMetabolic CARE"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-1080","article-title":"Impact of oral semaglutide on kidney outcomes in people with type 2 diabetes: results from the SOUL randomized trial","volume":"49","author":"Mann JF","year":"2026","unstructured":"Mann JF, Marx N, Deanfield JE, et al.. Impact of oral semaglutide on kidney outcomes in people with type 2 diabetes: results from the SOUL randomized trial. Diabetes Care. 2026, 49:257-65. 10.2337\/dc25-1080","journal-title":"Diabetes Care"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo EM","year":"2025","unstructured":"Apperloo EM, Gorriz JL, Soler MJ, et al.. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2025, 31:278-85. 10.1038\/s41591-024-03327-6","journal-title":"Nat Med"},{"key":"ref71","unstructured":"ClinicalTrials.gov. REDEFINE 3. a research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels. Accessed: May 18, 2026: https:\/\/clinicaltrials.gov\/study\/NCT05669755."},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24332","article-title":"Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial","volume":"33","author":"Lam CS","year":"2025","unstructured":"Lam CS, Rodriguez A, Aminian A, et al.. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obesity (Silver Spring). 2025, 33:1645-56. 10.1002\/oby.24332","journal-title":"Obesity (Silver Spring)"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.09.004","article-title":"Survodutide for the treatment of obesity: rationale and design of the SYNCHRONIZE cardiovascular outcomes trial","volume":"12","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Platz E, Wharton S, et al.. Survodutide for the treatment of obesity: rationale and design of the SYNCHRONIZE cardiovascular outcomes trial. JACC Heart Fail. 2024, 12:2101-9. 10.1016\/j.jchf.2024.09.004","journal-title":"JACC Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/500321-evaluating-the-cardiovascular-benefits-of-innovator-semaglutide-24-mg-recombinant-dna-r-dna-in-patients-with-overweight-or-obesity-a-critical-review-of-current-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:28:35Z","timestamp":1782181715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/500321-evaluating-the-cardiovascular-benefits-of-innovator-semaglutide-24-mg-recombinant-dna-r-dna-in-patients-with-overweight-or-obesity-a-critical-review-of-current-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":73,"URL":"https:\/\/doi.org\/10.7759\/cureus.111322","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}